-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AP-301 in Hyperphosphatemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AP-301 in Hyperphosphatemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AP-301 in Hyperphosphatemia Drug Details: VS-505 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EMB-07 in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EMB-07 in Metastatic Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EMB-07 in Metastatic Pancreatic Cancer Drug Details: EMB-07 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AP-306 in Hyperphosphatemia In Chronic Kidney Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AP-306 in Hyperphosphatemia In Chronic Kidney Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AP-306 in Hyperphosphatemia In Chronic Kidney Disease Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JNJ-8543 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JNJ-8543 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. JNJ-8543 in Diffuse Large B-Cell Lymphoma Drug Details: JNJ-80948543...
-
Product Insights
IgA Nephropathy (Berger’s Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘IgA Nephropathy (Berger's Disease) - Drugs In Development, 2023’, provides an overview of the IgA Nephropathy (Berger's Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for IgA Nephropathy (Berger's Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Polycystic Kidney Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Polycystic Kidney Disease - Drugs In Development, 2023’, provides an overview of the Polycystic Kidney Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Hyperphosphatemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Hyperphosphatemia - Drugs In Development, 2023’, provides an overview of the Hyperphosphatemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hyperphosphatemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Hyperphosphatemia In Chronic Kidney Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Hyperphosphatemia In Chronic Kidney Disease - Drugs In Development, 2023’, provides an overview of the Hyperphosphatemia In Chronic Kidney Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) - Drugs In Development, 2023’, provides an overview of the Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...